OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...
OPKO Health has improved its financial position by selling most of BioReference, reducing cash burn, and strengthening its balance sheet. Ngenla's profit share with Pfizer has underperformed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback